JUNEL 1/20
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JUNEL 1/20 (JUNEL 1/20).
Combination estrogen-progestin contraceptive. Ethinyl estradiol is a synthetic estrogen that suppresses gonadotropin release by inhibiting hypothalamic GnRH secretion. Norethindrone acetate is a progestin that suppresses LH surge and thickens cervical mucus to inhibit sperm penetration and alters endometrial development.
| Metabolism | Ethinyl estradiol is primarily metabolized by CYP3A4, with additional contributions from CYP2C9 and CYP2C19. Norethindrone acetate is metabolized via reduction and conjugation (glucuronidation and sulfation). Both undergo first-pass metabolism in the liver and intestinal wall. |
| Excretion | Renal: 30-50% (metabolites as glucuronide and sulfate conjugates). Fecal: 20-40% (biliary elimination of metabolites). Unchanged drug: <5% renal. |
| Half-life | Ethinyl estradiol: 12-24 hours (terminal half-life). Norethindrone: 5-14 hours (terminal half-life). Achieves steady state within 5-7 days. |
| Protein binding | Ethinyl estradiol: 97-98% bound to albumin and SHBG. Norethindrone: 90% bound to albumin and SHBG. |
| Volume of Distribution | Ethinyl estradiol: 2.5-4.0 L/kg. Norethindrone: 2.5-4.0 L/kg. Large Vd indicates extensive tissue distribution. |
| Bioavailability | Oral: Ethinyl estradiol 38-48% (first-pass metabolism). Norethindrone 50-65% (first-pass metabolism). |
| Onset of Action | Oral: Contraceptive effect requires 7 days of continuous dosing; for immediate effect, start on day 1 of menstrual period. |
| Duration of Action | 24 hours (daily dosing required). Clinical note: Missed pills reduce contraceptive efficacy; back-up method needed if >2 pills missed. |
| Molecular Weight | 376.5 (ethinyl estradiol) + 312.4 (norethindrone) average ~344.45 Da (as combination) |
| Action Class | Oral Contraceptive; Estrogen-Progestin Combination |
One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days, then repeat.
| Dosage form | TABLET |
| Renal impairment | No specific GFR-based dose adjustment; contraindicated in patients with renal impairment if associated with hyperkalemia or other contraindications. |
| Liver impairment | Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For mild impairment (Child-Pugh A), use with caution; no specific dose adjustment established. |
| Pediatric use | Post-menarche adolescents: same dosing as adults (1 tablet daily for 21 days, then 7 placebo days). Weight-based dosing not applicable. |
| Geriatric use | Not indicated for postmenopausal women; use only in reproductive-age individuals. |
| 1st trimester | Contraindicated due to risk of congenital anomalies; non-hormonal contraception recommended. |
| 2nd trimester | Avoid use; may be associated with adverse fetal outcomes. |
| 3rd trimester | Avoid use; theoretical risk of neonatal estrogenization and withdrawal symptoms. |
Clinical note
Comprehensive clinical and safety monograph for JUNEL 1/20 (JUNEL 1/20).
| Placental transfer | Estrogens and progestins cross the placenta; evidence of transfer with clinical significance. |
| Breastfeeding | Small amounts of estrogen/progestin excreted in breast milk; may reduce milk production and quality. Not recommended during breastfeeding. |
| Lactation Rating |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age (especially in women over 35 years) and with the number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
| Common Effects | Nausea, Headache, Breast tenderness, Weight changes, Irregular uterine bleeding, Mood changes |
| Serious Effects | Venous thromboembolism (deep vein thrombosis, pulmonary embolism), Arterial thromboembolism (myocardial infarction, stroke), Hepatic adenoma or hepatocellular carcinoma, Hypertension, Gallbladder disease, Cerebrovascular events |
PregnancyBreast cancerEstrogen-dependent neoplasiaUndiagnosed abnormal uterine bleedingActive liver disease or impaired liver functionThromboembolic disorders or historyCerebrovascular or coronary artery diseaseKnown or suspected endometrial carcinomaHepatic adenomas or carcinomasDiabetes with vascular involvementHeadaches with focal neurological symptoms (migraine with aura)Major surgery with prolonged immobilization
| Precautions |
Loading safety data…
| L4 (Possibly Hazardous) |
| Teratogenic Risk | FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester: Use associated with congenital anomalies, including cardiovascular defects and neural tube defects. Second and third trimesters: May cause fetal harm, including feminization of male fetuses and other adverse outcomes. Discontinue immediately if pregnancy occurs. |
| Fetal Monitoring | Monitor blood pressure, blood glucose, liver function, and lipid profile regularly. Assess for thromboembolic events. Perform pregnancy test prior to initiation and if pregnancy suspected. Fetal monitoring not indicated as drug is contraindicated in pregnancy. |
| Fertility Effects | Suppresses ovulation. May cause delayed return to fertility after discontinuation; return to baseline ovulation typically occurs within 1-3 months. No permanent effect on fertility. |
| Increased risk of thromboembolic events (e.g., stroke, MI, DVT, PE), Hepatic neoplasia (benign and malignant), Gallbladder disease, Hypertension, Carbohydrate and lipid effects, Ocular changes (e.g., retinal thrombosis), Headache/migraine, Bleeding irregularities, Depression, Carcinoma risks (breast, cervical), Hereditary angioedema, Chloasma, Reduced efficacy with concomitant CYP3A4 inducers, Pregnancy (should be ruled out before use) |
| Food/Dietary | No known significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically relevant. Avoid St. John's wort (herbal supplement) as it induces CYP3A4 and reduces contraceptive efficacy. |
| Clinical Pearls | Junel 1/20 is a low-dose combined oral contraceptive (COC) containing ethinyl estradiol 20 mcg and norethindrone acetate 1 mg. It is indicated for contraception but not for emergency contraception. Monitor for breakthrough bleeding, especially in first 3 months. CYP3A4 inducers (e.g., rifampin, St. John's wort) may reduce efficacy. Risk of venous thromboembolism (VTE) is lower than with 30-35 mcg EE pills but still present; counsel about smoking cessation if >35 years old. |
| Patient Advice | Take one tablet daily at the same time; if a pill is missed, follow package instructions. · Use backup contraception (e.g., condoms) for the first 7 days of starting or after a missed pill. · Do not smoke while on this medication, especially if over 35, as it increases the risk of blood clots. · Report signs of blood clots (leg pain/swelling, sudden chest pain, difficulty breathing) or liver problems (yellow skin/eyes, dark urine). · Antibiotics (except rifampin) do not reduce contraceptive efficacy; verify with pharmacist. · Mild side effects (nausea, headache, breast tenderness) often improve after 2-3 cycles. |